The art of doing more with less: What Mangalyaan Mission and Sarvam AI have in common

A Mars orbiter for $74 million, heart surgery for $1,600 and AI without cloud bills — India’s frugal engineering model is reshaping the economics of innovation.

• India's Mars mission succeeded at one-ninth NASA's cost
• Aravind Eye Care offers cataract surgery starting at $29 per eye
• Sarvam AI enables on-device AI, cutting ongoing cloud costs

Did our AI summary help?

In November 2013, a modest rocket lifted off from Sriharikota carrying India’s first interplanetary probe. The mission would later orbit Mars successfully on its first attempt. The cost: $74 million.

For comparison, NASA’s MAVEN Mars mission, launched around the same time, cost about $671 million. That makes India’s Mars Orbiter Mission, popularly known as Mangalyaan, roughly one-ninth the price (one-third of the cost of the Hollywood film Gravity).

India’s space agency relied on its Polar Satellite Launch Vehicle, a workhorse rocket refined over years. The payload was lean. The team was small, roughly 100 engineers. The timeline was tight, just 18 months from approval to launch. Fewer layers, fewer redundancies, fewer frills.

The result was not a compromise mission. Mangalyaan reached Mars orbit on the first attempt, a feat even some advanced space programs have stumbled over. It proved something larger: world-class outcomes do not always require world-class budgets.

That lesson runs through several of India’s most striking innovations.

The $30 surgery

At Aravind Eye Care in Tamil Nadu, cataract surgery can cost as little as $29 per eye, including the intraocular lens. In the United States, Medicare reimbursement alone often exceeds $2,500 when facility and surgeon fees are combined.

The gap is dramatic. The outcomes are not.

Studies published in journals such as The Lancet have noted that Aravind’s complication rates are comparable to, and in some cases lower than, those in Western systems. How?

Volume and specialisation. Surgeons at Aravind may perform up to 65 surgeries a day. Operating rooms function almost like assembly lines: while a surgeon works on one patient, nurses prepare the next. The hospital manufactures its own lenses through Aurolab, slashing input costs. Patients who can pay subsidise those who cannot.

The economics are relentless. Fixed costs get diluted. Waste is squeezed out. Efficiency becomes culture.

The $40 prosthetic

The Jaipur Foot prosthetic limb, developed in the 1970s, costs roughly $40 to manufacture using locally available rubber and wood. Comparable prosthetics in Western markets can cost $8,000 or more.

More than a million amputees have been fitted with Jaipur Foot devices globally. Many walk within hours of fitting. The model depends on open workshops, volunteer labor and simple materials, not carbon fibre composites or microprocessors.

It is not high-tech elegance. It is high-impact practicality.

The bargain-baseline aircraft carrier

INS Vikrant, commissioned in 2022, is widely estimated to have cost about Rs 200,000 million (around $2.5 billion).

That number sits in a notably lower bracket than many peers: the UK’s HMS Queen Elizabeth has been reported at roughly £3.5 billion (about $4.5 billion at typical exchange rates), the US Navy’s Gerald R. Ford class is around $13 billion, and Russia’s Vikramaditya refit has been pegged near $2.9 billion.

The cost story runs through domestic design and construction at Cochin Shipyard, conventional propulsion rather than nuclear, and a phased approach that reduced 'big-bang' R&D risk.

The payoff isn’t just hardware. India joined a small club, often put at around 10 countries. that have built an aircraft carrier largely on their own, turning shipbuilding from a one-off project into an accumulating national capability.

The Polio Week

In 2003, India vaccinated 165 million children against polio in a single week. The oral polio vaccine cost mere cents per dose. The campaign mobilised 1.3 million health workers and volunteers.

By 2014, India was declared polio-free.

The cost per child was tiny by Western standards, where injectable vaccines and delivery logistics can raise expenses substantially. But scale, government coordination and partnerships with UNICEF and WHO drove down per-dose costs. When volume is enormous, margins shrink and impact multiplies.

The $35 tablet and the $2,500 car

The Aakash tablet, launched in 2011 at a subsidised price of about $35, aimed to bring digital access to students. Comparable entry-level tablets globally cost four to five times as much. The device was basic, 7-inch display, modest memory, but it was functional. Over a million units were distributed.

The Tata Nano, unveiled at roughly $2,500, was billed as the world’s cheapest car. It stripped away non-essentials: no radio, optional air conditioning, simplified engineering. Commercially, it struggled. Symbolically, it demonstrated that cost compression could be engineered deliberately.

Not every low-cost experiment becomes a blockbuster. But each pushes the boundary of what is possible at a given price point.

Chandrayaan-3 

Chandrayaan-3 made India the first country to land near the Moon’s south pole and costed Rs 615 crore (~$75 million).

ISRO reused Chandrayaan-2 infrastructure, optimised mass, and avoided heavy-lift launch architecture.

While NASA's Artemis, which costed $4.1 billion, is a broader program, the comparison underscores the structural cost gap between India’s incremental lunar engineering and NASA’s deep-space architecture model.

India demonstrated a credible lunar capability at under $100 million.

The low-cost vaccine machine

India’s vaccine rollout in 2021–22 put another kind of cost advantage on display: industrial scale backed by state bargaining power.

Covishield and Covaxin were priced in private hospitals at around Rs 225 per dose after revisions, numbers that looked small against reported Western-market pricing, where comparable vaccines were often cited in the $20–30 range.

In rough ratio terms, India’s per-dose pricing landed at a sliver of rich-market headlines. The mechanism was straightforward: massive local manufacturing capacity with Serum Institute as a central player, technology partnerships and transfers (including the Oxford/AstraZeneca tie-up for Covishield and Bharat Biotech’s work on Covaxin), and government-negotiated bulk procurement that pushed prices down.

The output wasn’t just cheaper doses, it was volume and speed, with India administering about 1.85 billion doses by mid-2022.

And it doubled as geopolitics: exports under Vaccine Maitri turned low-cost manufacturing into both public health delivery and diplomatic leverage.

Now, AI Without the Cloud Bill

The latest entrant in this lineage is Sarvam AI, an Indian artificial intelligence startup focused on on-device models.

Most AI services rely on cloud inference. Each query can carry a marginal cost, fractions of a cent, perhaps, but multiplied billions of times. Sarvam’s approach embeds compact language and speech models directly onto devices, eliminating per-query cloud fees.

The upfront compute cost is absorbed during device integration. After that, inference is effectively free.

If Mangalyaan showed that Mars exploration need not cost hundreds of millions, Sarvam suggests that AI need not depend on constant cloud billing. It is the same philosophy applied to silicon instead of steel.

What Ties These Stories Together

The common thread is not simply low labor cost, though that helps. It is system design.

High throughput spreads fixed costs thin. Simple designs reduce failure points. Local supply chains avoid import markups. Task-shifting improves efficiency. Public-private partnerships create scale. Subsidies, where used, aim to catalyze adoption.

There are trade-offs. The Tata Nano’s stripped-down approach hurt consumer appeal. Ultra-high volumes can strain quality control if not managed carefully. On-device AI models may lack the scale of cloud-based giants.

But repeatedly, India’s experience shows that efficiency can coexist with effectiveness. Aravind’s surgical outcomes are internationally respected. India’s polio campaign is cited globally as a public health triumph. ISRO’s space program has built credibility across missions.